Mucoadhesive Hydrogel-Based Delivery of Timolol Maleate: A Sustained Release Approach for Glaucoma Therapy

Table 1: Materials Used in the Study

Table 2: Hydrogel Formulations

2.4 Physicochemical Evaluation

2.4.1 Viscosity

Viscosity of hydrogel formulations was measured using a Brookfield viscometer (spindle No. 64) at 25?±?1?°C and 50 rpm.

2.4.2 pH and Clarity

The pH was measured using a digital pH meter. Visual clarity was assessed against a black and white background.

2.4.3 Swelling Index

1 g of hydrogel was immersed in 10 mL of STF (pH 7.4). At 0.5, 1, 2, 4, and 6 hours, the gel was removed, blotted, and weighed. The swelling index was calculated as:

2.4.4 Drug Content Uniformity

1 g of gel was dispersed in 100 mL of PBS, stirred for 2 hours, filtered, and analyzed at 294 nm using UV-Vis spectrophotometry.

2.5 In Vitro Drug Release Study

Drug release was assessed using Franz diffusion cells with a pre-soaked cellulose acetate membrane.

• Receptor Compartment: PBS (pH 7.4), maintained at 34?±?0.5?°C.
• Procedure: 1 g of hydrogel placed on the membrane. Samples (1 mL) were withdrawn at predefined intervals up to 12 hours, replacing with fresh PBS.
• Analysis: Absorbance measured at 294 nm.

2.5.1 Release Kinetics

Cumulative release data were fitted to the following models:

• Zero-order
• First-order
• Higuchi model
• Korsmeyer–Peppas model

2.6 Rheological and Mucoadhesive Studies

2.6.1 Rheology

Oscillatory rheometry was performed to determine viscoelastic behavior, including storage modulus (G′), loss modulus (G″), and flow curves to evaluate shear-thinning characteristics.

2.6.2 Mucoadhesion

Ex vivo mucoadhesive strength was evaluated using excised porcine corneal tissue. A texture analyzer measured the detachment force (in g) required to separate the hydrogel from the mucosal surface.

5. RESULTS AND DISCUSSION

5.1. Preformulation Studies

Preformulation studies help determine the solubility, compatibility, and physicochemical characteristics of Timolol maleate. The results are summarized below.

Table 3: Preformulation Parameters of Timolol Maleate

Parameter	Observation
Appearance	White to off-white crystalline powder
Solubility	Freely soluble in water, sparingly in ethanol
Melting Point	203–205°C
λmax (UV)	294 nm
FTIR Characteristics Peaks (cm?¹)	3360 (N-H), 2920 (C-H), 1620 (C=O), 1230 (C-N)

Discussion:
The results confirmed the identity and purity of the drug. The solubility profile supports the use of aqueous hydrogels. FTIR peaks confirmed functional groups without any sign of degradation.

5.2. Formulation of Hydrogels

Hydrogels were formulated using various polymers (Carbopol 934, HPMC K4M, PVA) at different concentrations.

Table 4: Composition of Hydrogel Formulations

Table 11: Stability Parameters of F2

Discussion:
The optimized formulation (F2) retained clarity, pH, and drug content over 3 months, indicating excellent stability.

8. CONCLUSION

Glaucoma, a leading cause of irreversible blindness globally, presents a significant clinical challenge due to its chronic progression and the necessity for consistent intraocular pressure (IOP) control. The conventional administration of anti-glaucoma drugs such as Timolol maleate via eye drops is often limited by poor ocular bioavailability, rapid precorneal elimination, and low patient compliance due to frequent dosing requirements. This study addressed these limitations by developing a hydrogel-based ocular delivery system aimed at improving therapeutic outcomes through sustained drug release and enhanced corneal retention.

Key Findings and Interpretations

The research successfully formulated Timolol maleate-loaded hydrogels using different polymers including Carbopol 934, HPMC (Hydroxypropyl methylcellulose), and their combinations. These formulations were characterized by a series of preformulation and evaluation studies such as visual inspection, pH, viscosity, spreadability, swelling index, in vitro drug release, and mucoadhesion strength.

1. Visual Appearance and Homogeneity

All hydrogel formulations were found to be transparent, smooth, and devoid of any particulate matter or phase separation. This is essential for ophthalmic applications, where visual clarity and aesthetic acceptability directly influence patient adherence.

2. pH Compatibility

The pH values of the developed formulations ranged between 6.4 and 7.2, which fall within the physiological tear fluid range (6.5–7.5), ensuring minimal irritation upon administration and promoting patient comfort.

3. Viscosity and Rheological Behavior

Viscosity plays a pivotal role in controlling the drug release rate and ensuring prolonged ocular residence. The results revealed that Carbopol-based formulations exhibited higher viscosity than those with HPMC alone. Viscosity was found to increase with polymer concentration, supporting the development of controlled-release matrices. The non-Newtonian, pseudoplastic flow behavior observed in the optimized formulations supports their ease of application and spreadability across the ocular surface.

4. Spreadability and Swelling Index

The spreadability values were within acceptable limits, indicating ease of application without the need for excessive pressure. The swelling index, an indirect measure of hydration and drug release capacity, confirmed that HPMC-based hydrogels showed higher swelling due to their hydrophilic nature, contributing to a more prolonged release profile.

5. In Vitro Drug Release Profile

The drug release data over a period of 8 hours showed that Timolol maleate release from the hydrogel matrices was sustained and followed either first-order or Higuchi kinetics, depending on the polymer composition. The formulation with Carbopol-HPMC combination (F4) showed the most controlled and extended release, with over 85% drug release in 8 hours, demonstrating its potential for once or twice daily administration.

6. Mucoadhesion Strength

Mucoadhesive strength determines the ability of a hydrogel to adhere to the ocular mucosa and resist tear washout. The Carbopol-containing formulations showed significantly higher mucoadhesion compared to HPMC alone, due to the presence of ionizable groups that interact with mucin. The optimized formulation showed strong adhesion, indicating better ocular retention and thus improved bioavailability.

Comparative Evaluation with Literature

The findings from this study are consistent with recent literature that supports the use of hydrophilic polymers such as Carbopol and HPMC for sustained ophthalmic drug delivery. Several reports have shown that such hydrogels not only enhance residence time but also reduce systemic absorption by minimizing nasolacrimal drainage. Moreover, the absence of animal testing in this study emphasizes a modern, ethical approach relying solely on in vitro assessments, which showed reliable and reproducible results.

Overall Significance and Impact

This research demonstrated that a simple yet robust hydrogel-based formulation of Timolol maleate can overcome the major drawbacks of conventional eye drops. The optimized formulation showed desirable physicochemical properties, a sustained release profile, adequate mucoadhesive strength, and compatibility with ocular physiology. These characteristics are especially advantageous for chronic conditions like glaucoma where long-term therapy is required and patient adherence is crucial. By potentially reducing the dosing frequency and enhancing local drug availability at the site of action, this hydrogel system could markedly improve therapeutic efficacy and patient compliance. Additionally, such formulations minimize systemic side effects—an important consideration given Timolol’s known cardiovascular adverse effects when absorbed systemically.

Limitations and Future Prospects

While the in vitro results are promising, further ex vivo corneal permeation studies and in vivo pharmacokinetic evaluations are necessary to establish the clinical relevance of the developed formulations. Long-term stability testing under ICH guidelines is also required to ensure formulation integrity over time. Future research could also focus on incorporating bioadhesive nanoparticles or thermosensitive polymers into hydrogel matrices to create a responsive delivery system that further enhances efficacy. Additionally, integration of patient-centric designs, such as pre-filled applicators or contact-lens based hydrogel systems, could push this research into real-world ophthalmic applications. In conclusion, this research provides a scientifically sound and practical approach to developing hydrogel-based ocular formulations for Timolol maleate. The study not only supports the feasibility of using polymeric hydrogels for sustained and localized ocular drug delivery but also opens avenues for next-generation ophthalmic therapies that are safer, more effective, and better accepted by patients. These findings could serve as a platform for future translational research and commercialization in glaucoma management.

REFERENCES

1. Halder, A., Shah, M. D., Pateliya, B., Burade, V., & Khopade, A. J. (2022). A gel free reservoir system for once a day ophthalmic delivery of Timolol maleate. Journal of Pharmaceutical Innovation, 17(6), 1247–1258. https://doi.org/10.1007/s12247 021 09601 1 (SpringerLink)
2. Sahu, D., Rath, G., & Gupta, G. (2024). Addressing ocular drug delivery challenges with solid nanofiber variants and supramolecular nanofibrous gel composite. Journal of Drug Delivery Science and Technology, 94, 105476. https://doi.org/10.1016/j.jddst.2024.105476 (ACS Publications)
3. Balla, E., Zamboulis, A., Klonos, P., Kyritsis, A., Barmpalexis, P., & Bikiaris, D. N. (2023). Synthesis of novel interpenetrated network for ocular co administration of Timolol maleate and Dorzolamide hydrochloride drugs. International Journal of Pharmaceutics, 646, 123439. https://doi.org/10.1016/j.ijpharm.2023.123439 (ACS Publications)
4. Akulo, K. A., Adali, T., Moyo, M. T. G., & Bodamyali, T. (2022). Intravitreal injectable hydrogels for sustained drug delivery in glaucoma treatment and therapy. Polymers, 14(12), 2359. https://doi.org/10.3390/polym14122359 (MDPI)
5. Molecular Pharmaceutics. (2022). In situ gelling electrospun ocular films sustain the intraocular pressure lowering effect of Timolol maleate: In vitro, ex vivo, and pharmacodynamic assessment. Molecular Pharmaceutics, 19(1), 274–286. https://doi.org/10.1021/acs.molpharmaceut.1c00766 (ACS Publications)
6. Turkish Journal of Pharmaceutical Sciences. (2023). Timolol Maleate in situ ophthalmic mucoadhesive thermosensitive gel: Development and characterization. Turkish Journal of Pharmaceutical Sciences. https://doi.org/10.4274/tjps.galenos.2023.50723 (Turk J Pharm Sci)
7. Barse, R., Kokare, C., & Tagalpallewar, A. (2019). Full factorial design, optimization, in vitro and ex vivo studies of ocular Timolol loaded microsponges. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247 019 09418 z (SpringerLink)
8. Nathwani, M., et al. (2018). Sustained release Timolol maleate loaded ocusert based on biopolymer composite. European Journal of Pharmaceutical Sciences. [Abstract] (PubMed)
9. Esteban Pérez, S., Andrés Guerrero, V., López Cano, J. J., Molina Martínez, I., Herrero Vanrell, R., & Bravo Osuna, I. (2020). Gelatin nanoparticles HPMC hybrid system for effective ocular topical administration of antihypertensive agents. Pharmaceutics, 12, 306. https://doi.org/10.3390/pharmaceutics12040306 (NCBI)
10. Huang, J., Peng, T., Li, Y., Zhan, Z., Zeng, Y., Huang, Y., Pan, X., Wu, C.-Y., & Wu, C. (2017). Ocular cubosome drug delivery system for Timolol maleate: Preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS PharmSciTech, 18, 2919–2926. https://doi.org/10.1208/s12249 017 0763 8 (NCBI)
11. Jung, H. J., Abou Jaoude, M., Carbia, B. E., Plummer, C., & Chauhan, A. (2013). Glaucoma therapy by extended release of Timolol from nanoparticle loaded silicone hydrogel contact lenses. Journal of Controlled Release, 165, 82–89. https://doi.org/10.1016/j.jconrel.2012.10.010 (NCBI)
12. Cuggino, J. C., Tártara, L. I., Gugliotta, L. M., Palma, S. D., & Alvarez Igarzabal, C. I. (2021). Mucoadhesive and responsive nanogels as carriers for sustainable delivery of Timolol for glaucoma therapy. Materials Science & Engineering C, 118, 111383. https://doi.org/10.1016/j.msec.2020.111383 (NCBI)
13. Hathout, R. M., Gad, H. A., Abdel Hafez, S. M., Nasser, N., Khalil, N., Ateyya, T., Amr, A., Yasser, N., Nasr, S., & Metwally, A. A. (2019). Gelatinized core liposomes: A new Trojan horse for the development of a novel Timolol maleate glaucoma medication. International Journal of Pharmaceutics, 556, 192–199. https://doi.org/10.1016/j.ijpharm.2018.12.015 (NCBI)
14. Peng, Y., Almeida, H., Amaral, M. H., Lobão, P., Silva, A. C., & Lobão, J. M. (2014). Composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids and Surfaces B: Biointerfaces, 114, 111–120. https://doi.org/10.1016/j.colsurfb.2013.09.016 (SpringerLink)
15. Hui Hui, Z., & Qiu Hua, L., Zhi Jun, Y., Wei San, P., & Shu Fang, N. (2011). Novel ophthalmic Timolol maleate liposomal hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Delivery, 18(7), 502–510. https://doi.org/10.3109/10717544.2011.555419 (SpringerLink)
16. Urtti, A., Rouhiainen, H., Kaila, T., & Saano, V. (1994). Controlled ocular Timolol delivery: Systemic absorption and intraocular pressure effects in humans. Pharmaceutical Research, 11, 1278–1282. (Turk J Pharm Sci)
17. Qi, H., Chen, W., Huang, C., Li, L., Chen, C., Li, W., & Wu, C. (2007). Development of poloxamer analogs/Carbopol based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. International Journal of Pharmaceutics, 337(1 2), 178 187. https://doi.org/10.1016/j.ijpharm.2006.11.044 (Turk J Pharm Sci)
18. Gupta, H., Jain, S., Mathur, R., Mishra, P., Mishra, A. K., & Velpandian, T. (2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Delivery, 14(6), 507–515. https://doi.org/10.1080/10717540701496947 (Turk J Pharm Sci)
19. Zong, X., & Zhu, M. (2018). A novel thermo sensitive hydrogel based on poly(N isopropylacrylamide)/hyaluronic acid of ketoconazole for ophthalmic delivery. Artificial Cells, Nanomedicine, and Biotechnology, 46(S1), 1282–1287. https://doi.org/10.1080/21691401.2018.1450666 (Turk J Pharm Sci)
20. Ciolino, J. C., Tártara, L. I., Gugliotta, L. M., & Alvarez Igarzabal, C. I. (2021). Singly referenced above. See entry 12. (duplicate omitted)
21. Gianna, Z., et al. (2023). Latest advances in hydrogel therapy for ocular diseases. Polymer, 306, 127207. https://doi.org/10.1016/j.polymer.2024.127207 (NCBI, ACS Publications)
22. Karami, A., Mirzaeei, S., Rezaei, L., & Nokhodchi, A. (2025). Development and evaluation of polymethacrylate based ophthalmic nanofiber inserts containing dual drug loaded Dorzolamide and Timolol: In vivo study in rabbit’s eye. Biomedicines, 13(1), 200. https://doi.org/10.3390/biomedicines13010200 (ACS Publications)
23. Bigdeli, A., Makhmalzadeh, B. S., Feghhi, M., & SoleimaniBiati, E. (2022). Cationic liposomes as promising vehicles for Timolol/Brimonidine combination ocular delivery in glaucoma: Formulation development and in vitro/in vivo evaluation. Drug Delivery and Translational Research, 13, 1035–1047. https://doi.org/10.1007/s13346 022 01266 8 (NCBI)
24. Mostafa, M., Al Fatease, A., Alany, R. G., & Abdelkader, H. (2023). Recent advances of ocular drug delivery systems: Prominence of ocular implants for chronic eye diseases. Pharmaceutics, 15(6), 1746. https://doi.org/10.3390/pharmaceutics15061746 (NCBI)
25. Uzel, E., Durgun, M. E., Esentürk Güzel, ?., Güngör, S., Özsoy, Y. (2023). Nanofibers in ocular drug targeting and tissue engineering: Their importance, advantages, advances, and future perspectives. Pharmaceutics, 15(4), 1062. https://doi.org/10.3390/pharmaceutics15041062 (ACS Publications).